Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Spectrum Failed To Heed FDA Advice On Apaziquone, And Is Paying The Price

Executive Summary

FDA's original advice against NDA submission foreshadows advisory committee conclusion that substantial evidence of efficacy in bladder cancer not demonstrated by two negative trials and a post hoc pooled analysis.


Related Content

Spectrum's Apaziquone Pooled Analysis Can't Make Up For Negative Studies
Spectrum's Apaziquone: Can Two Failed Studies Lead To An Approval?
Hanmi, Spectrum Look For Differentiation As Poziotinib Progresses
Spectrum regains apaziquone from Allergan, to file US NDA on pooled data
Spectrum Hopes For Synergies With Allos Acquisition Amid Phase III Setback


Related Companies

Related Deals

What to read next




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts